Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Ascletis Pharma, Inc. ( (HK:1672) ).
Ascletis Pharma has selected ASC30_39 FDC, a fixed-dose oral tablet combining its once-daily GLP-1 receptor agonist ASC30 and amylin-selective receptor agonist ASC39, as a new clinical candidate for obesity. The company plans to submit an Investigational New Drug application to the U.S. FDA in the third quarter of 2026, positioning itself in the fast-growing market for oral obesity treatments.
In preclinical dog studies, the ASC30_39 FDC tablets showed oral bioavailability, drug exposure and a half-life of up to 12 hours that were comparable to the individual monotherapies. The fixed-dose combination also demonstrated good compatibility, room-temperature stability and a small pill size, supporting its potential as a once-daily, single-pill regimen that could enhance patient convenience and outcomes in obesity care.
ASC30, which is Phase III-ready, has shown a more favorable gastrointestinal tolerability profile with about half the vomiting rate of orforglipron under weekly titration conditions in separate studies. ASC39 has demonstrated potent, eloralintide-like amylin selectivity and efficacy in preclinical models, and the company believes that combining these mechanisms in an oral format may deliver synergistic efficacy and strengthen Ascletis’s competitive position in metabolic disease therapeutics.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a Cayman Islands–incorporated biopharmaceutical company listed in Hong Kong that focuses on developing innovative oral small-molecule therapies. Its pipeline targets major metabolic and viral diseases, and it is now emphasizing treatments for obesity through next-generation oral hormone receptor agonists.
Average Trading Volume: 2,787,230
Technical Sentiment Signal: Buy
Current Market Cap: HK$18.02B
Find detailed analytics on 1672 stock on TipRanks’ Stock Analysis page.